Tirzepatide and Body Fluid Volume in Obesity With Preserved-Ejection Heart Failure
Studies how tirzepatide changes plasma volume in people with obesity and HFpEF.
Key facts
- Who runs it
- Columbia University
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Incretin Therapies in Obesity-related HFpEF
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 50 people, planned
- Started
- 7 Aug 2026
- Expected to end
- Apr 2030
- Type of study
- Interventional
- Treatments tested
- Tirzepatide
- Record updated
- 24 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity and heart failure with preserved ejection fraction (HFpEF) who clinically qualify for treatment with tirzepatide.
- Age
- 40 years or older
- Sex
- All sexes
- Disease stage
- Heart failure with NYHA class II-III symptoms, left ventricular ejection fraction >= 45% within 6 months, and body mass index (BMI) >30 kg/m2. At least one sign of heart strain or structural heart disease is also needed.
- Earlier treatment
- Stable doses of heart failure medicines within 4 weeks of screening, with well-controlled fluid levels in the investigator's opinion.
- Biomarker or test result
- At least one of these: NT-proBNP >=200 pg/ml (>=600 pg/ml with atrial fibrillation), a enlarged left atrium, or high heart filling pressures on tests.
Main reasons for not taking part
- Acute decompensated heart failure within 4 weeks of screening
- Heart attack or stroke within 90 days of screening
- Another cause of HFpEF, such as cardiac amyloidosis, hypertrophic cardiomyopathy or severe valve disease
- eGFR <15 ml/min/1.73m2 or dependence on dialysis
- Type 1 diabetes, or poorly controlled diabetes (A1c > 9.5% (80 mmol/mol))
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Diagnosis of heart failure (HF) per the ACC/AHA guidelines with NYHA class II-III symptoms
- Left ventricular ejection fraction >= 45% within 6 months of recruitment
- At least one of the following: elevated N-terminal pro- B-type natriuretic peptide (NT-proBNP) >=200 pg/ml (>=600 pg/ml with concurrent atrial fibrillation), evidence of structural heart disease (left atrial (LA) enlargement with LA volume index >29 mL/m2 or LA diameter >=40 mm in males/>38= mm in females), elevated filling pressures (resting wedge >15 mmHg or exercise wedge >25 mmHg, lateral E/e' ratio >12 or septal E/e' > 15)
- Body mass index (BMI) >30 kg/m2
- Stable doses of HF medications within 4 weeks of screening with optimal volume control in the opinion of the investigator
Who cannot take part
- Major cardiovascular event within 90 days of screening (myocardial infarction, stroke)
- Alternate cause of HFpEF such as cardiac amyloidosis, infiltrative cardiomyopathy, hypertrophic cardiomyopathy, severe valvular disease
- Poorly controlled diabetes (A1c > 9.5%) OR any type 1 diabetes mellitis
- History of acute or chronic pancreatitis
- Personal or family history of multiple endocrine neoplasia (MEN) or medullary thyroid cancer
- Estimated glomerular fibrilation rate (EGFR) <15 ml/min/1.73m2 or dialysis dependence
- Acute decompensated HF within 4 weeks of screening
- Clinically significant gastric emptying abnormality
- Medical comorbidities that limit survival
- Inability to comply with the study protocol
- Pregnancy
Where in United States
- Columbia University Irving Medical Center (CUIMC) / NewYork Presbyterian Hospital (NYP)New York, United StatesContact: Jessica IdumonyiTaking people
About the trial
What the trial wants to find out
The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. In conjunction with state-of-the-art body composition analysis and measures of adipokines, this will establish an important mechanism of clinical benefit and inform disease pathophysiology. To accomplish this, this study will perform a 15-month prospective cohort study in 50 patients with obesity and HFpEF who clinically qualify for treatment with tirzepatide. The investigators will serially measure plasma volume and body composition with quantitative magnetic resonance to determine changes over time with tirzepatide treatment.
The group in the trial
- TirzepatideTreatment being tested
After a 3-month control period, participants will be prescribed tirzepatide and undergo serial plasma volume measurement and body composition analysis. Participants will be prescribed tirzepatide under the brand name Monjauro if they have diabetes, and under the brand name Zepbound if they do not have diabetes. All participants will be initiated on an initial dose of 2.5 mg injected subcutaneously in the thigh or abdomen every week on same day and at the same time.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Identifying Therapeutic Mechanisms for Incretin-Based Treatment in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF)
- Plain-language title
- Tirzepatide and Body Fluid Volume in Obesity With Preserved-Ejection Heart FailureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 24 August 2026